Spots Global Cancer Trial Database for malignant melanoma stage iii
Every month we try and update this database with for malignant melanoma stage iii cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT01302496 | Malignant Melan... Malignant Melan... | TriMix-DC and i... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab | NCT02977052 | Malignant Melan... | Ipilimumab Nivolumab Surgery Blood for PBMCs Biopsies | 18 Years - | The Netherlands Cancer Institute | |
| mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma | NCT01676779 | Malignant Melan... Malignant Melan... | Dendritic cell ... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) | NCT03493230 | Malignant Melan... Malignant Melan... | quantification ... | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | NCT01189383 | Malignant Melan... Malignant Melan... | IL15-DC Vaccine | 21 Years - 75 Years | Baylor Research Institute | |
| Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT ) | NCT03493230 | Malignant Melan... Malignant Melan... | quantification ... | 18 Years - | Centre Hospitalier Universitaire de Nice | |
| Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | NCT04949113 | Malignant Melan... | Neoadjuvant ipi... Adjuvant nivolu... | 16 Years - | The Netherlands Cancer Institute | |
| Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma | NCT01302496 | Malignant Melan... Malignant Melan... | TriMix-DC and i... | 18 Years - | Universitair Ziekenhuis Brussel | |
| The IRMI-FMT Trial | NCT04577729 | Fecal Microbiot... Malignant Melan... Malignant Melan... | Allogenic Fecal... Autologous Feca... | 18 Years - | Medical University of Graz | |
| The IRMI-FMT Trial | NCT04577729 | Fecal Microbiot... Malignant Melan... Malignant Melan... | Allogenic Fecal... Autologous Feca... | 18 Years - | Medical University of Graz | |
| Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma | NCT04133948 | Malignant Melan... | Domatinostat Nivolumab Ipilimumab | 18 Years - | The Netherlands Cancer Institute | |
| Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | NCT04949113 | Malignant Melan... | Neoadjuvant ipi... Adjuvant nivolu... | 16 Years - | The Netherlands Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
